TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05205109: A Phase I/Ib, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG-037 Monotherapy and Combination Therapy With Pembrolizumab in Patie

Sponsor: Antengene Therapeutics Limited · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 98 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT05205109 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05205109 Rescue Dossier →